JAK1/2-deficient cells emerged under/after ICB in patients with advanced melanoma and obtained resistance to PD-L1 blockade, which may result from pre-existing heterogenous subclones or through an adaptive response [9, 176, 177]. The gene discussed is CD274; the disease is melanoma.